Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic
hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC)
in patients with refractory/relapsed MCL and CLL with poor prognostic factors. Acalabrutinib
will be used before alloSCT with the intention to reduce tumor burden and after transplant to
augment disease control.